Wiggans Thomas G's Form 4 filing
Pardes Biosciences, Inc. (PRDS) · filed Dec 5, 2022
- Accession no.
- 0001209191-22-059677
- Filed
- Dec 5, 2022
- Trade date
- Dec 1-2, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market purchases total $39.4K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Wiggans Thomas GCIK 0001208907 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price in Column 4 is a weighted average purchase price. The prices actually paid ranged from $0.96025 to $1.05.
Referenced by the price of 1 transaction in Table I.
- F2
The reporting person undertakes to provide upon request by the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range.
Referenced by the price of 2 transactions in Table I.
- F3
The price in Column 4 is a weighted average purchase price. The prices actually paid ranged from $1.02 to $1.12.
Referenced by the price of 1 transaction in Table I.